- Home
- EYEN vs ACXP Comparison
EYEN vs ACXP Comparison
Compare EYEN & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EYEN
- ACXP
- Stock Information
- Founded
- EYEN 2014
- ACXP 2017
- Country
- EYEN United States
- ACXP United States
- Employees
- EYEN N/A
- ACXP N/A
- Industry
- EYEN Biotechnology: Pharmaceutical Preparations
- ACXP Biotechnology: Pharmaceutical Preparations
- Sector
- EYEN Health Care
- ACXP Health Care
- Exchange
- EYEN Nasdaq
- ACXP Nasdaq
- Market Cap
- EYEN 38.2M
- ACXP 31.4M
- IPO Year
- EYEN 2018
- ACXP 2021
- Fundamental
- Price
- EYEN $0.10
- ACXP $1.72
- Analyst Decision
- EYEN Buy
- ACXP Strong Buy
- Analyst Count
- EYEN 3
- ACXP 1
- Target Price
- EYEN $12.00
- ACXP $12.00
- AVG Volume (30 Days)
- EYEN 3.7M
- ACXP 39.1K
- Earning Date
- EYEN 11-12-2024
- ACXP 11-12-2024
- Dividend Yield
- EYEN N/A
- ACXP N/A
- EPS Growth
- EYEN N/A
- ACXP N/A
- EPS
- EYEN N/A
- ACXP N/A
- Revenue
- EYEN $31,832.00
- ACXP N/A
- Revenue This Year
- EYEN $50,943.04
- ACXP N/A
- Revenue Next Year
- EYEN $397.57
- ACXP N/A
- P/E Ratio
- EYEN N/A
- ACXP N/A
- Revenue Growth
- EYEN 2557.10
- ACXP N/A
- 52 Week Low
- EYEN $0.09
- ACXP $1.52
- 52 Week High
- EYEN $2.57
- ACXP $5.28
- Technical
- Relative Strength Index (RSI)
- EYEN 18.14
- ACXP 28.13
- Support Level
- EYEN $0.46
- ACXP $1.82
- Resistance Level
- EYEN $0.51
- ACXP $1.89
- Average True Range (ATR)
- EYEN 0.05
- ACXP 0.08
- MACD
- EYEN -0.03
- ACXP -0.01
- Stochastic Oscillator
- EYEN 3.11
- ACXP 28.10
About EYEN Eyenovia Inc.
Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.